Composite severity assessment for alpha-1 antitrypsin deficiency using Pi typing, serum A1AT level, FEV1 percent predicted, DLCO, and liver fibrosis markers to guide augmentation therapy decisions.
Composite severity assessment for alpha-1 antitrypsin deficiency using Pi typing, serum A1AT level, FEV1 percent predicted, DLCO, and liver fibrosis markers to guide augmentation therapy decisions
Each component has a specific meaning:
Note: Interpret the a1at severity result against the thresholds and context described above.
Enter the Pi typing, serum A1AT level, FEV1 percent predicted, DLCO, liver fibrosis markers for the scenario you are assessing. Composite severity assessment for alpha-1 antitrypsin deficiency using Pi typing, serum A1AT level, FEV1 percent predicted, DLCO, and liver fibrosis markers to guide augmentation therapy decisions. Use the a1at severity result to inform your calculation.